HR 1223 · 115th Congress 2017โ€“2019, ended

OPEN Act

Latest action · Mar 3, 2017 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedFeb 27, 2017
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 or the OPEN Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Department of Health and Human Services (HHS) to extend by six months the exclusivity period for a drug or biological product approved by the Food and Drug Administration (FDA) when the product is additionally approved to prevent, diagnose, or treat a new indication that is a rare disease or condition (also known as an orphan disease).

HHS may revoke an extension if the application submitted to the FDA for the new indication contained an untrue material statement.

HHS must notify the public of products that receive this extension and patents related to those products.

Products may receive only one extension under this bill. Extensions under this bill are in addition to other extensions.

The bill applies only to products approved after enactment of this bill for a new indication that is a rare disease or condition.

Cosponsors 43

Members who signed on, in the order they did. Signatures ran from Feb 27, 2017 to Oct 16, 2018; 2 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
D-NCG. K. ButterfieldOriginalFeb 27, 2017
R-TXMichael T. McCaulOriginalFeb 27, 2017
D-FLDarren SotoMar 1, 2017
R-NJLeonard LanceMar 1, 2017
R-NJRodney P. FrelinghuysenMar 1, 2017
D-CAAnna G. EshooMar 8, 2017
R-NYDaniel M. Donovan, Jr.Mar 8, 2017
R-PATim MurphyMar 8, 2017
D-NJDonald NorcrossMar 16, 2017
R-OKMarkwayne MullinMar 16, 2017
D-CAJared HuffmanMar 24, 2017
R-NEJeff FortenberryMar 24, 2017
R-FLDaniel WebsterApr 3, 2017
R-NEDon BaconApr 3, 2017
R-MSSteven M. PalazzoMay 22, 2017
R-FLFrancis RooneyJun 12, 2017
D-CAZoe LofgrenJun 23, 2017
R-WACathy McMorris RodgersJun 27, 2017
D-NJAlbio SiresJun 28, 2017
D-CAEric SwalwellJun 28, 2017
R-MIFred UptonJul 11, 2017
R-TXPete OlsonJul 12, 2017
R-MOBilly LongJul 28, 2017
D-NHCarol Shea-PorterSep 5, 2017
R-ALMo BrooksSep 5, 2017
R-OHSteve StiversSep 13, 2017
D-MOWm. Lacy ClayOct 11, 2017
D-FLAlcee L. HastingsMar 5, 2018
R-VABarbara ComstockMar 5, 2018
R-PABrian K. FitzpatrickMar 5, 2018
R-NJChristopher H. SmithMar 5, 2018
D-NMMichelle Lujan GrishamMar 6, 2018
R-IADavid YoungApr 10, 2018
R-TXJohn Abney CulbersonMay 1, 2018
D-NYKathleen M. RiceJun 12, 2018
D-NJBonnie Watson ColemanJun 19, 2018
D-INPeter J. ViscloskyJul 17, 2018
R-WADavid G. ReichertJul 31, 2018
R-FLBill PoseyAug 28, 2018
R-INLuke MesserAug 28, 2018
R-ILPeter J. RoskamAug 31, 2018
R-TXTed PoeSep 4, 2018
D-NCDavid E. PriceOct 16, 2018

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Feb 27, 2017
Health Subcommittee
Referred Mar 3, 2017

Actions 3

Everything that happened, newest first.

  1. Mar 3, 2017Referred to the Subcommittee on Health.
  2. Feb 27, 2017Introduced in House
  3. Feb 27, 2017Referred to the House Committee on Energy and Commerce.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article I, Section 8, Clause 1, which gives the Congress the authority to provide for the general welfare of the United States. Additionally, under Article I, Section 8, Clause 8 which gives Congress the power to promote the progress of science and useful arts by securing for limited times to authors and inventors the exclusive right to their respective writings and discoveries.

The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 34, February 27, 2017, page H1355.

Printed hearings 1

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
S. Hrg. 115-403THE 30TH ANNIVERSARY OF TRIBAL SELF-GOVERNANCE: SUCCESSES IN SELF- GOVERNANCE AND AN OUTLOOK FOR THE NEXT 30 YEARS49 pagesIndian Affairs CommitteeApr 18, 2018

Related bills 1

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 1509Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017Related billJun 29, 2017

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Federal Food, Drug, and Cosmetic Act to authorize an extension of exclusivity periods for certain drugs that are approved for a new indication for a rare disease or condition, and for other purposes.
Short Titles as Introduced
OPEN Act
Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Feb 27, 2017Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.